- Trials with a EudraCT protocol (113)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
113 result(s) found for: Small intestine.
Displaying page 2 of 6.
| EudraCT Number: 2022-000849-32 | Sponsor Protocol Number: 1/2022 | Start Date*: 2022-05-10 |
| Sponsor Name:Helsinki University Hospital | ||
| Full Title: The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight | ||
| Medical condition: HIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000244-42 | Sponsor Protocol Number: acid_permeability_healthyvolunteers | Start Date*: 2015-04-21 | |||||||||||
| Sponsor Name:KU Leuven | |||||||||||||
| Full Title: The role of mast cells on duodenal permeability after duodenal acid perfusion in healthy volunteers | |||||||||||||
| Medical condition: To investigate the role of mast cells on duodenal permeability after duodenal acid perfusion. The study will be done in healthy volunteers and the results will give an indication about the role of ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-004426-10 | Sponsor Protocol Number: MO28072 | Start Date*: 2012-05-11 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual partici... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-002586-34 | Sponsor Protocol Number: STEROID_MC_1 | Start Date*: 2020-11-12 | |||||||||||||||||||||||||||||||
| Sponsor Name:Department of Anesthesiology, Copenhagen University Hospital Hvidovre, Capital Region of Denmark | |||||||||||||||||||||||||||||||||
| Full Title: The effects of preoperative high-dose Dexamethasone on inflammatory response and recovery after emergency laparotomy, a randomized, double-blind, placebo-controlled clinical trial - AHA STEROID ... | |||||||||||||||||||||||||||||||||
| Medical condition: Patients undergoing emergency laparotomy due to either Intestinal obstruction or perforated abdominal viscus. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-001156-22 | Sponsor Protocol Number: DDD16APREPITANT | Start Date*: 2016-07-19 |
| Sponsor Name:KU Leuven - Drug Delivery and Disposition | ||
| Full Title: The gastrointestinal behavior of aprepitant in healthy volunteers | ||
| Medical condition: healthy human volunteers (administration of an drug against nausea and vomiting | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-005074-12 | Sponsor Protocol Number: 20070411 | Start Date*: 2009-03-04 | |||||||||||||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||||||||||||
| Full Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Es... | |||||||||||||||||||||||
| Medical condition: Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. --------------------... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2021-002264-41 | Sponsor Protocol Number: IMGC936-0901 | Start Date*: 2022-02-21 | |||||||||||||||||||||||||||||||
| Sponsor Name:ImmunoGen, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-004678-16 | Sponsor Protocol Number: INCB24360-207 | Start Date*: 2018-05-31 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with solid tumors of the type of colorectal cancer, pancreatic ductal adenocarcinoma, Squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, any solid tumor that pro... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-005076-26 | Sponsor Protocol Number: SGNTV-001 | Start Date*: 2019-04-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Seagen, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-001199-12 | Sponsor Protocol Number: MLN0002/CCT-001 | Start Date*: 2019-05-28 |
| Sponsor Name:Takeda | ||
| Full Title: Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induct... | ||
| Medical condition: This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous Vedolizumab (300 mg) infusi... | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016083-36 | Sponsor Protocol Number: CS7017-A-U204 | Start Date*: 2010-10-21 | ||||||||||||||||
| Sponsor Name:Daiichi Sankyo Pharma Development | ||||||||||||||||||
| Full Title: Phase 2 Study of CS-7017 and Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy | ||||||||||||||||||
| Medical condition: Treatment of patients with advanced non-small cell lung cancer (NSCLC) after failure of prior chemotherapy regimen | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-001080-36 | Sponsor Protocol Number: 20150195 | Start Date*: 2016-11-17 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Amgen Incorporated | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging data | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2004-000439-27 | Sponsor Protocol Number: CL0600-005 | Start Date*: 2007-10-29 |
| Sponsor Name:NPS Allelix Corporation | ||
| Full Title: A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004 | ||
| Medical condition: Short Bowel Syndrome (SBS) refers to the clinical situation whereby a significant reduction in the absorptive capacity of the intestine results from inadequate anatomical or functional length of re... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-002217-22 | Sponsor Protocol Number: SJ-546 | Start Date*: 2016-09-02 | ||||||||||||||||
| Sponsor Name:Sjællands University Hospital, Køge | ||||||||||||||||||
| Full Title: Validation of stimulated ∆FGF19 for diagnosing bile acid diarrhoea | ||||||||||||||||||
| Medical condition: Bile acid malabsorption / bile acid diarrhoea | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-003475-42 | Sponsor Protocol Number: GTAEXS617-001 | Start Date*: 2023-05-23 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Exscientia AI Ltd | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: advanced solid tumors | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-004989-25 | Sponsor Protocol Number: INCAGN1876-201 | Start Date*: 2017-09-28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Phase 1: advanced or metastatic cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma (mucosal or cutaneous), Merkel cell carcinoma, mesothelioma, MSI-H colorectal... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-004415-39 | Sponsor Protocol Number: TO-TAS0728-101 | Start Date*: 2019-02-05 | |||||||||||||||||||||||||||||||
| Sponsor Name:Taiho Oncology, Inc. | |||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS W... | |||||||||||||||||||||||||||||||||
| Medical condition: Urothelial cancer with HER2 or HER3 mutation Biliary tract cancer with HER2 or HER3 mutation Breast cancer with HER2 or HER3 mutation Breast cancer with HER2 amplification/overexpression as per AS... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-004163-12 | Sponsor Protocol Number: 2020-012-GLOB1 | Start Date*: 2021-11-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | |||||||||||||||||||||||||||||||||
| Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-001111-12 | Sponsor Protocol Number: 1367.1 | Start Date*: 2015-06-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:SCS Boehringer Ingelheim Comm.V | ||||||||||||||||||||||||||||||||||||||
| Full Title: An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced, unresectable and/or metastatic solid tumours, which have failed with conventional treatment or for which no therapy of proven efficacy exists, or in patients who are not amenable to stand... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-001439-11 | Sponsor Protocol Number: DDD16BICARBONATE | Start Date*: 2016-06-28 |
| Sponsor Name:KU Leuven - Drug Delivery and Disposition | ||
| Full Title: Influence of bicarbonate on drug gastrointestinal behaviour and disposition | ||
| Medical condition: Healthy human volunteers (administration of an antipyretic, analgetic drug) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
